Skip to main content
SpringerLink
Log in

Immunogenicity of a recombinant pre-S2-containing hepatitis B vaccine versus plasma-derived vaccine administered as a booster

  • Article
  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

Abstract

GenHevac B Pasteur is a recombinant hepatitis B vaccine derived from a mammalian cell line and containing HBs as well as pre-S2 antigens. Its immunogenicity was compared to that of the plasma-derived vaccine Hevac B Pasteur in a population primovaccinated 5.5 years earlier with four injections of the same plasma vaccine. The booster injection with either GenHevac or Hevac was administered to 295 subjects with residual anti-HBs titres below 500 IU/l (group 1: 0–9; group 2: 10–99; group 3: 100–499 IU/l). After four weeks, GenHevac had induced higher anti-HBs responses than Hevac in all groups, particularly among the low responders of group 1. Response to the vaccine occurred earlier with GenHevac. Mean anti-pre-S2 production was moderate in all groups for both vaccines (GenHevac: 60 IU/l; Hevac: 31 IU/l) and was not found in the 32 subjects who produced less than 100 IU/l anti-HBs. The results of the present study indicate that GenHevac is at least as immunogenic as Hevac.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Adamowicz G, Gerfaux A, Platel L, Muller B, Vacher BC, Prunet P Large scale production of an hepatitis B vaccine. In: Maupas P, Guesry P (ed): Hepatitis B vaccine. INSERM Symposium No. 18. Elsevier/North Holland Biomedical Press, Amsterdam, 1981, p. 37–49.

    Google Scholar 

  2. Goudeau A, Dubois F, Barin F, Dubois MC Le vaccin contre l'hépatite virale B. Huit ans d'expérience en milieu hospitalier. Louvain Medical 1983, 102: 77–98.

    Google Scholar 

  3. Rossier P, Peitrequin R, Frei PC Campagne de vaccination contre l'hépatite B, pratiquée de 1982 à 1984 avec le vaccin Hevac B Pasteur, chez 6162 employés des hôpitaux vaudois. Schweizerische Medizinische Wochenschrift 1987, 117: 629–637.

    PubMed  Google Scholar 

  4. Heermann KH, Goldmann U, Schwartz W, Seyffarth T, Baumgarten H, Gerlich WH Large surface proteins of hepatitis B virus containing the pre-S sequence. Journal of Virology 1984, 52: 396–402.

    PubMed  Google Scholar 

  5. Tiollais P, Pourcel C, Dejean A The hepatitis B virus. Nature 1985, 317: 489–495.

    Article  PubMed  Google Scholar 

  6. Miller RH, Kaneko S, Chung CT, Girones R, Purcell RH Compact organization of the hepatitis B virus genome. Hepatology 1989, 9: 322–327.

    PubMed  Google Scholar 

  7. Milich DR, Thornton GB, Neurath AR, Kent SB, Michel ML, Tiollais P, Chisari FV Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen. Science 1985, 228: 1195–1199.

    PubMed  Google Scholar 

  8. Milich DR, McLachlan A, Chisari FV, Nakamura T, Thornton GB Two distinct but overlapping antibody binding sites in the pre-S2 region of HBsAg localized within 11 continuous residues. Journal of Immunology 1986, 137: 2703–2710.

    Google Scholar 

  9. Milich DR, McLachlan A, Chisari FV, Thornton GB Nonoverlapping T and B cell determinants on an hepatitis B surface antigen pre-S2 region synthetic peptide. Journal of Experimental Medicine 1986, 164: 532–547.

    Article  PubMed  Google Scholar 

  10. Itoh Y, Takai E, Ohnuma H, Kitajima K, Tsuda F, Machida A, Mishiro S, Nakamura T, Miyakawa Y, Mayumi M A synthetic peptide involving the product of the pre-S2 region of hepatitis B virus DNA: protective efficacy in chimpanzees. Proceedings of the National Academy of Sciences of the USA 1986, 83: 9174–9178.

    PubMed  Google Scholar 

  11. Neurath AR, Kent SBH, Parker K, Prince AM, Strick N, Brotman B Sproul P Antibodies to a synthetic peptide from the pre-S 120–145 region of the hepatitis B virus envelope are virus-neutralizing. Vaccine 1986, 4: 35–37.

    PubMed  Google Scholar 

  12. Charbit A, Sobczak E, Michel ML, Molla A, Tiollais P, Hofnung M Presentation of two epitopes of the pre-S2 region of hepatitis B virus on live recombinant bacteria. Journal of Immunology 1987, 139: 1658–1664.

    Google Scholar 

  13. Machida A, Kishimoto S, Ohnuma H, Miyamoto K, Baba K, Oda K, Nakamura T, Miyakawa Y, Mayumi M A hepatitis B surface antigen polypeptide (P31) with the receptor for polymerized human as well as chimpanzee albumins. Gastroenterology 1983, 85: 268–274.

    PubMed  Google Scholar 

  14. Budkowska A, Dubreuil P, Capel F, Pillot J Hepatitis B virus pre-S gene-encoded antigenic specificity and anti-pre-S antibody: relationship between anti-pre-S response and recovery. Hepatology 1986, 6: 360–368.

    PubMed  Google Scholar 

  15. Ishihara K, Waters JA, Pignatelli M, Thomas HC Characterisation of the polymerised and monomeric human serum albumin binding sites on hepatitis B surface antigen. Journal of Medical Virology 1987, 21: 89–95.

    PubMed  Google Scholar 

  16. Thung SN, Wang DF, Fasy TM, Hood A, Gerber MA Hepatitis B surface antigen binds to human serum albumin cross-linked by transglutaminase. Hepatology 1989, 9: 726–730.

    PubMed  Google Scholar 

  17. Alberti A, Pontisso P, Tagariello G, Cavalletto D, Chemello L, Belussi F Antibody response to pre-S2 and hepatitis B virus induced liver damage. Lancet 1988, i: 1421–1424.

    Article  Google Scholar 

  18. Budkowska A, Dubreuil P, Pillot J Prognostic value of pre-S2 epitopes of hepatitis B virus and anti-pre-S2 response evaluated by monoclonal assays. In: Zuckerman AJ (ed): Viral hepatitis and liver disease. Alan R. Liss, Inc., New York, 1988, p. 287–289.

    Google Scholar 

  19. Kurai K, Iino S, Koike K, Mitamura K, Endo Y, Oka H serum titers of pre-S2 antigen in patients with acute and chronic type B hepatitis: relation to serum aminotransferase activity and other hepatitis B virus markers. Hepatology 1989, 9: 175–179.

    PubMed  Google Scholar 

  20. Hadziyannis S, Raimondo G, Papaioannou C, Anastassakos C, Wong D, Sninsky J, Shafritz D Expression of pre-S gene-encoded proteins in liver and serum during chronic hepatitis B infection in comparison to other markers of active virus replication. Journal of Hepatology 1987, 5: 253–259.

    Article  PubMed  Google Scholar 

  21. Ibarra MZ, Mora I, Bartolomé J, Porres JC, Carreno V Detection of proteins encoded by the pre-S region of hepatitis B virus in the sera of HBsAg carriers: relation to viral replication. Liver 1989, 9: 153–158.

    PubMed  Google Scholar 

  22. Coursaget P, Adamowicz P, Bourdil C, Yvonnet B, Buisson Y, Barrès JL, Saliou P, Chiron JP, Diop Mar, I Anti-pre-S2 antibodies in natural hepatitis B infection and after immunization. Vaccine 1988, 6: 357–361.

    Article  PubMed  Google Scholar 

  23. Fujisawa Y, Kuroda S, Van Eerd PMCA, Schellekens H, Kakinuma A Protective efficacy of a novel hepatitis B vaccine consisting of M (pre-S2 + S) protein particles (a third generation vaccine), Vaccine 1990, 8: 192–198.

    Article  PubMed  Google Scholar 

  24. Michel ML, Pontisso P, Sobczak E, Malpièce Y, Streeck RE, Tiollais P Synthesis in animal cells of hepatitis B surface antigen particles carrying a receptor for polymerized human serum albumin. Proceedings of the National Academy of Sciences of the USA 1984, 81: 7708–7712.

    PubMed  Google Scholar 

  25. Adamowicz P, Tron F, Vinas R, Mevelec MN, Diaz I, Couroucé AM, Mazert MC, Lagarde D, Girard M Hepatitis B vaccine containing the S and pre-S2 antigens produced in Chinese hamster ovary cells. In: Zuckerman AJ (ed): Viral hepatitis and liver disease. Alan R. Liss, Inc., New York, 1988, p. 1087–1090.

    Google Scholar 

  26. Degos F, Tron F, Benhamou JP Virus de l'hépatite B et vaccination. Médecine/Sciences 1988, 4: 629–636.

    Google Scholar 

  27. Lavanchy D, Fritzell B, Geudelin B, Peitrequin R, Frei PC Anti-pre-S2 antibody response in subjects vaccinated against hepatitis B and in naturally immunized subjects. Research in Virology 1991, 142: 363–371.

    Article  PubMed  Google Scholar 

  28. Jilg W, Schmidt M, Zachoval R, Deinhardt F Persistenz von Antikörpern gegen Hepatitis-B-Oberflächenantigen nach Impfung gegen Hepatitis B. Deutsche Medizinische Wochenschrift 1985, 110: 205–209.

    PubMed  Google Scholar 

  29. Zanetti A, Tanzi E, Mannucci PM Dissociated antibody responses to the S and pre-S2 regions of the hepatitis B virus after vaccination in hemophiliacs. Journal of Medical Virology 1989, 28: 156–158.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Immunology and Allergology, Centre Hospitalier Universitaire Vaudois, CH-1011, Lausanne, Switzerland

    B. Bucher, D. Lavanchy & P. C. Frei

  2. Division of Hospital Preventive Medicine, Centre Hospitalier Universitaire Vaudois, CH-1011, Lausanne, Switzerland

    P. Francioli

  3. Sanofi Winthrop, CH-4142, Münchenstein, Switzerland

    B. Geudelin

  4. Pasteur Mérieux Sérums et Vaccins, F-92430, Marnes-La-Coquette, France

    B. Fritzell

Authors
  1. B. Bucher
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Francioli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. Geudelin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B. Fritzell
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D. Lavanchy
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P. C. Frei
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bucher, B., Francioli, P., Geudelin, B. et al. Immunogenicity of a recombinant pre-S2-containing hepatitis B vaccine versus plasma-derived vaccine administered as a booster. Eur. J. Clin. Microbiol. Infect. Dis. 13, 212–217 (1994). https://doi.org/10.1007/BF01974539

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01974539

Keywords

Search

Navigation